Vincent Rajkumar, MD's Avatar

Vincent Rajkumar, MD

@vincentrk

Editor in Chief, Blood Cancer Journal; Professor, Mayo Clinic; Associate Editor, Mayo Clinic Proceedings; Oncologist, Cancer Research, Myeloma.

6,433
Followers
13
Following
13
Posts
12.11.2024
Joined
Posts Following

Latest posts by Vincent Rajkumar, MD @vincentrk

Post image

Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM

5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...

18.10.2025 12:57 πŸ‘ 13 πŸ” 3 πŸ’¬ 0 πŸ“Œ 0

So excited to see this thread on BlueSky, @vincentrk.bsky.social! Thank you as always for your excellent summaries!

09.12.2024 17:52 πŸ‘ 10 πŸ” 1 πŸ’¬ 1 πŸ“Œ 0

Wow. I’m overwhelmed by the response here. Will post more on here.

22.12.2024 23:35 πŸ‘ 21 πŸ” 0 πŸ’¬ 2 πŸ“Œ 0

It is through clinical trials that new treatments are discovered, tested, and approved.

A medicine is a chemical and will stay so in the absence of clinical trials.

No trial, no medicines.
I’m thankful for colleagues who run clinical trials.
#ASH24

08.12.2024 15:56 πŸ‘ 17 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0
Post image

9. All the active drugs for myeloma in one simple table. Black font = approved drugs; blue font = investigational.

08.12.2024 15:56 πŸ‘ 14 πŸ” 1 πŸ’¬ 1 πŸ“Œ 0

8. Will post hot-of-the-press smoldering myeloma SMM treatment algorithm Monday afternoon #ASH24

AQUILA trial!
Stay tuned.

08.12.2024 15:56 πŸ‘ 3 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Preview
Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management Disease overview Multiple myeloma accounts for approximately 10% of hematologic malignancies. Diagnosis The diagnosis requires β‰₯10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma ...

7. For more details check out my 2024 Annual myeloma diagnosis and treatment update published in Am J Hematology. #OpenAccess
#ASH24 onlinelibrary.wiley.com/doi/10.1002/...

08.12.2024 15:56 πŸ‘ 3 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Preview
mSMART

6. In general if possible and available a clinical trial is preferable to these algorithms.

These are general principles. You have to individualize treatment selection. Also treatments evolve. Follow msmart.org for updates
@MayoMyeloma #ASH24

08.12.2024 15:56 πŸ‘ 1 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Post image

5. True Penta-Refractory myeloma (refractory to PI, Imid, CD38, alkylator, and BCMA targeted approach).
msmart.org #ASH24

08.12.2024 15:56 πŸ‘ 2 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Post image

4. Second or later relapse
mSMART.org #ASH24

08.12.2024 15:56 πŸ‘ 2 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Post image

3) First Relapse

I don’t recommend CART in first relapse even though it’s approved except in very selected patients (eg., high risk progressing early while on quad).

msmart.org #ASH24

08.12.2024 15:56 πŸ‘ 2 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Post image

2. Newly diagnosed transplant eligible. Quadruplet induction.

See below for transplant timing and maintenance. #ASH24

08.12.2024 15:56 πŸ‘ 2 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Post image

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24
#ASH24VR

1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.

08.12.2024 15:56 πŸ‘ 32 πŸ” 6 πŸ’¬ 1 πŸ“Œ 1

My first post here.

Holy cow! And I already have followers here! Thanks so much everyone.

I’m still trying to figure out how to post on X and here.
#ASH24

08.12.2024 00:11 πŸ‘ 37 πŸ” 0 πŸ’¬ 6 πŸ“Œ 0